Jay Precision Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
as on 16-07-2024
- Paid Up Capital ₹ 4.01 Cr
as on 16-07-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 35.67%
(FY 2022)
- Profit 24.37%
(FY 2022)
- Ebitda 20.65%
(FY 2022)
- Net Worth 3.80%
(FY 2022)
- Total Assets 4.58%
(FY 2022)
About Jay Precision Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 4.01 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Jay Precision Pharmaceuticals Private Limited India are Mandar Kurghode as COMPANY SECRETARY and Sanjive Baranwal as Cfo. Dinesh Jain, Amrita Nautiyal, Xerxes Rao, and Four other members serve as directors at the Company.
- CIN/LLPIN
U33111MH2012PTC234037
- Company No.
234037
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 2012
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jay Precision Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Xerxes Rao  | Managing Director | 01-Aug-2012 | Current |
| Mandar Kurghode | Company Secretary | 24-Aug-2021 | Current |
| Sanjive Baranwal | CFO | 11-Apr-2024 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Zubin Rao | Director | 02-Jan-2020 | Current |
| Dinesh Jain | Director | 01-Apr-2022 | Current |
| Amrita Nautiyal | Director | 10-Sep-2019 | Current |
| Geena Malhotra | Director | 26-Feb-2015 | Current |
| Chandrashekhar Iyer | Director | 10-Sep-2019 | Current |
| Achin Gupta | Director | 03-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Jay Precision Pharmaceuticals.
Jay Precision Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 35.67% increase. The company also saw a substantial improvement in profitability, with a 24.37% increase in profit. The company's net worth moved up by a moderate rise of 3.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jay Precision Pharmaceuticals?
In 2023, Jay Precision Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Cipla Pharmaceuticals LimitedActive 5 years 1 month
Dinesh Jain and Geena Malhotra are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jay Precision Pharmaceuticals?
Jay Precision Pharmaceuticals has a workforce of 438 employees as of Jun 19, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jay Precision Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jay Precision Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
